Key result
Triple antiplatelet treatment (adding a glycoprotein IIb/IIIa inhibitor to aspirin and clopidogrel) is reviewed for its rationale and evidence in high-risk non-ST-segment elevation ACS patients.
Why the study?
Does triple antiplatelet treatment improve outcomes compared to dual antiplatelet treatment in high-risk patients with non-ST-segment elevation acute coronary syndromes?
Population
High-risk patients presenting with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)
Comparison
Triple antiplatelet treatment vs Dual antiplatelet treatment
Design
Review
Authors
Loading...
Evidence inconclusive for routine use in high-risk NSTE-ACS; leaves open need for contemporary RCTs.
Does triple antiplatelet treatment improve outcomes compared to dual antiplatelet treatment in high-risk patients with non-ST-segment elevation acute coronary syndromes?
This review discusses the rationale and evidence for adding a glycoprotein IIb/IIIa receptor inhibitor to aspirin and clopidogrel in high-risk patients with NSTE-ACS.
Bertrand et al. (2006) conducted a review in non-ST-segment elevation acute coronary syndromes. Triple antiplatelet treatment (aspirin, clopidogrel, and glycoprotein IIb/IIIa receptor inhibitor) vs. Dual antiplatelet treatment (aspirin and clopidogrel) was evaluated. Triple antiplatelet treatment (adding a glycoprotein IIb/IIIa inhibitor to aspirin and clopidogrel) is reviewed for its rationale and evidence in high-risk non-ST-segment elevation ACS patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: